GT200300098A - Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona - Google Patents
Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-trionaInfo
- Publication number
- GT200300098A GT200300098A GT200300098A GT200300098A GT200300098A GT 200300098 A GT200300098 A GT 200300098A GT 200300098 A GT200300098 A GT 200300098A GT 200300098 A GT200300098 A GT 200300098A GT 200300098 A GT200300098 A GT 200300098A
- Authority
- GT
- Guatemala
- Prior art keywords
- heteroariloxi
- ariloxi
- triona
- pyrimidina
- aril
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA COMO LA QUE SE MUESTRA EN EL RESUMEN EN DONDE R1,X,A,Y,B,G, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON INHIBIDORES DE LAS METALOPROTEINASAS POR LO QUE SON DE UTILIDAD EN CUADROS INFLAMATORIOS TALES COMO OSTEOARTRITIS O ARTRITIS REUMATOIDE RELACIONADOS CON EL TEJIDO CONJUNTIVO, ADEMAS DE UNA AMPLIA VARIEDAD DE PATOLOGIAS COMO ENFERMEDADES RESPIRATORIAS, CARDIOVASCULARES, OCULARES ENTRE OTRAS DESCRITAS EN LA SOLICITUD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37597402P | 2002-04-26 | 2002-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200300098A true GT200300098A (es) | 2004-05-18 |
Family
ID=29270739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200300098A GT200300098A (es) | 2002-04-26 | 2003-04-25 | Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona |
Country Status (15)
Country | Link |
---|---|
US (1) | US6919332B2 (es) |
EP (1) | EP1507535A1 (es) |
JP (1) | JP2005529889A (es) |
AR (1) | AR039660A1 (es) |
AU (1) | AU2003223012A1 (es) |
BR (1) | BR0309556A (es) |
CA (1) | CA2483500A1 (es) |
DO (1) | DOP2003000632A (es) |
GT (1) | GT200300098A (es) |
MX (1) | MXPA04010550A (es) |
PA (1) | PA8572101A1 (es) |
PE (1) | PE20040465A1 (es) |
TW (1) | TW200406407A (es) |
UY (1) | UY27775A1 (es) |
WO (1) | WO2003090751A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1572215B1 (en) | 2002-12-20 | 2009-09-02 | Glaxo Group Limited | Benzo[d]azepine derivatives for the treatment of neurological disorders |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
NZ571182A (en) | 2006-04-04 | 2010-09-30 | Univ California | Pyrazolo[3,4-d]pyrimidines |
UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
MY191407A (en) | 2008-01-04 | 2022-06-27 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
DK2358720T3 (en) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
DK2663309T3 (en) | 2011-01-10 | 2017-06-19 | Infinity Pharmaceuticals Inc | METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103946226A (zh) | 2011-07-19 | 2014-07-23 | 无限药品股份有限公司 | 杂环化合物及其应用 |
SG11201400310WA (en) | 2011-08-29 | 2014-06-27 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
BR112016007467B1 (pt) | 2013-10-04 | 2022-09-20 | Infinity Pharmaceuticals, Inc | Compostos heterocíclicos e usos dos mesmos |
JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物 |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10647692B2 (en) | 2015-03-12 | 2020-05-12 | Fmc Corporation | Heterocycle-substituted bicyclic azole pesticides |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
RU2758667C2 (ru) | 2015-12-14 | 2021-11-01 | Фмк Корпорейшн | Замещенные по гетероциклу бициклические азол пестициды |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
ES2951809T3 (es) | 2017-05-17 | 2023-10-25 | Arcus Biosciences Inc | Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN117003754A (zh) * | 2022-04-28 | 2023-11-07 | 腾讯科技(深圳)有限公司 | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
DE69831233T2 (de) | 1997-06-21 | 2006-06-01 | Roche Diagnostics Gmbh | Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung |
US6265578B1 (en) | 1999-02-12 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrimidine-2,4,6-triones |
HN2000000137A (es) * | 1999-08-12 | 2001-02-02 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
US6468686B1 (en) * | 2000-01-24 | 2002-10-22 | Graftech Inc. | Fluid permeable flexible graphite fuel cell electrode with enhanced electrical and thermal conductivity |
US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
EA200300409A1 (ru) * | 2000-10-26 | 2003-08-28 | Пфайзер Продактс Инк. | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы |
ES2247527T3 (es) | 2002-04-26 | 2006-03-01 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona. |
DE60302150D1 (en) | 2002-04-26 | 2005-12-08 | Pfizer Prod Inc | N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren |
NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
-
2003
- 2003-04-15 EP EP03718979A patent/EP1507535A1/en not_active Withdrawn
- 2003-04-15 JP JP2003587385A patent/JP2005529889A/ja active Pending
- 2003-04-15 AU AU2003223012A patent/AU2003223012A1/en not_active Abandoned
- 2003-04-15 BR BR0309556-8A patent/BR0309556A/pt not_active IP Right Cessation
- 2003-04-15 MX MXPA04010550A patent/MXPA04010550A/es not_active Application Discontinuation
- 2003-04-15 CA CA002483500A patent/CA2483500A1/en not_active Abandoned
- 2003-04-15 WO PCT/IB2003/001546 patent/WO2003090751A1/en not_active Application Discontinuation
- 2003-04-22 PE PE2003000399A patent/PE20040465A1/es not_active Application Discontinuation
- 2003-04-23 DO DO2003000632A patent/DOP2003000632A/es unknown
- 2003-04-23 PA PA20038572101A patent/PA8572101A1/es unknown
- 2003-04-24 UY UY27775A patent/UY27775A1/es not_active Application Discontinuation
- 2003-04-24 TW TW092109608A patent/TW200406407A/zh unknown
- 2003-04-24 AR ARP030101421A patent/AR039660A1/es unknown
- 2003-04-25 GT GT200300098A patent/GT200300098A/es unknown
- 2003-04-28 US US10/424,382 patent/US6919332B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6919332B2 (en) | 2005-07-19 |
JP2005529889A (ja) | 2005-10-06 |
WO2003090751A1 (en) | 2003-11-06 |
AU2003223012A1 (en) | 2003-11-10 |
US20030232849A1 (en) | 2003-12-18 |
BR0309556A (pt) | 2005-02-09 |
CA2483500A1 (en) | 2003-11-06 |
MXPA04010550A (es) | 2005-01-25 |
EP1507535A1 (en) | 2005-02-23 |
PA8572101A1 (es) | 2003-12-10 |
PE20040465A1 (es) | 2004-07-24 |
AR039660A1 (es) | 2005-03-02 |
DOP2003000632A (es) | 2003-10-31 |
TW200406407A (en) | 2004-05-01 |
UY27775A1 (es) | 2003-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200300098A (es) | Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona | |
GT200300093A (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida | |
GT200300097A (es) | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona | |
GT200300150A (es) | Inhibidores de quinasas | |
GT200300201A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
GT200200210A (es) | Alquinos como inhibidores de metaloproteinasa de matriz | |
GT200300087A (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
GT200200027A (es) | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz | |
RS52505B (en) | PHOSPHORAMIDATE ALKYLATER PRODUCTS | |
GT200500208A (es) | Indazoles ùtiles para tratar enfermedades cardiovasculares | |
GT200300226A (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos | |
GT200400020A (es) | Compuestos de triazol utiles en terapia | |
GT200400032A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
GT200600174A (es) | Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion | |
GT200300187A (es) | Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas | |
GT200600434A (es) | Tieno[2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa | |
GT200300171A (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz | |
PA8599601A1 (es) | Compuestos de benzopirano utiles para tratar estados inflamatorios | |
GT200600072A (es) | Composiciones farmaceuticas | |
DE602006016271D1 (de) | Reversible thermochromische Zusammensetzungen | |
GT200400188A (es) | 5-arilpirimidinas como agentes anticancerigenos | |
GT200400088A (es) | Pirazolopirimidinas sustituidas con 6-ciclilmetilo y 6-alquilmetilo | |
GT200600039A (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
GT200400142A (es) | Compuestos | |
GT200400232A (es) | Metodos y composiciones para la inhibicion de selectina |